Oracle to pay $100M settlement to Oregon over failed healthcare exchange site

Oregon and software company Oracle have reached a settlement agreement valued at more than $100 million over the state’s failed health insurance exchange “Cover Oregon,” according to a report from OPB.

Advertisement

The settlement involves cash payments to the state in addition to a six-year license agreement for products and services, according to the report. As a result, Oracle will continue operating and modernizing the state’s software systems.

Oregon’s primary issue with Oracle was that after spending $240 million on a website for the state’s health insurance exchange, the site didn’t work, according to the report. The state ended the Cover Oregon webpage in 2014 and has since used the federal exchange, HealthCare.gov.

Originally, Oregon demanded more than $6 billion in damages from Oracle and accused the company’s executives of fraud, filing false claims and racketeering. The two parties reached a settlement Thursday.

Oregon Gov. Kate Brown (D) pointed out the settlement will not only resolve “a chapter of public finger-pointing and failure,” but it will also be used to help support science education programs in the state’s public schools, according to the report.

 More articles on legal and regulatory issues:
DA finds potential misuse of hospital funds for lavish dinners at St. Bernard Parish Hospital
Lawmakers search for ways to regulate synthetic drug use
OIG’s Medicaid Fraud Control Unit’s FY 2015: 6 things to know

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.